Boundless Bio BOLD 深 沪
交易中 10-06 10:31:16 美东时间
2.515
-0.085
-3.27%
华盛通- 最 高3.1636
- 今 开2.62
- 成交量 2885股
- 最 低 2.42
- 昨 收 2.60
- 总市值 11.53万
- 52周最高 3.1636
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.9612
- 委 比 -94.94%
- 总股本 4.59万
- 历史最高 60.00
- 量 比 0.20
- 振 幅 28.60%
- 历史最低 0.9612
- 每 手 1
- 风险率 0.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dow Falls Over 300 Points; Korn Ferry Earnings Top Views
US stocks down as Dow falls 300 points, while S&P 500 and NASDAQ also decrease. Consumer staples rise, tech stocks fall. Korn Ferry beats earnings.
06-23 21:49
Boundless Bio Q4 EPS $(0.58) Misses $(0.52) Estimate
Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.52) by 11.54 percent. This is a 21.62 percent increase over losses of $(0.74) per share from
03-09 19:13
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Inspira Technologies Oxy (NASDAQ:IINN) shares increased by 25.9% to $0...
02-09 20:05
意达利控股旗下瀚德逊电动货车批量发运瑞士，欧洲市场拓展开启新征程
2025年9月12日，意达利控股(00720.HK)旗下瀚德逊汽车迎来了其发展历程中的又一重要里程碑，瀚德逊电动货车首次批量启运瑞士，这标志着瀚德逊在欧洲市场的...
2025-09-15 16:01
Boundless Bio Announces Portfolio Prioritization and Runway Extension
Boundless Bio announces portfolio prioritization focusing on BBI-355 and BBI-825 combination therapy, and BBI-940 for its Kinesin program. The company extends its cash runway into early 2028, discontinues certain clinical trial arms, and plans to initiate new trials in 2025. A webcast on May 27 will provide further details.
2025-05-23 20:01
